skip to main content

SITraN secures industry partnership to accelerate novel treatments for Parkinson’s and ALS

17 Oct 2018

  • New partnership will bring together leading researchers in the field of Parkinson’s, Amyotrophic Lateral Sclerosis (ALS) and mitochondrial biology with industry experts in chemistry and drug discovery
  • Parkinson’s disease is the most common form of movement disorder, which affects 145,000 people in the UK and 7-10 million people worldwide.
  • ALS is a devastating motor neuron disease that affects 5,000 people in the UK and 450,000 people worldwide.

Researchers from the University of Sheffield have secured a new partnership with a US-based biotechnology company to help progress their pioneering translational research.

The new collaboration with researchers at the University’s world-renowned Sheffield Institute of Translational Neuroscience (SITraN) and FORMA Therapeutics will focus on using patient cells to understand the complex biology underpinning Parkinson’s and Amyotrophic Lateral Sclerosis (ALS) and to harness this technology for novel drug discovery.

Parkinson’s disease is a debilitating condition which is relentlessly progressive. It currently affects 145,000 people in the UK, with numbers expected to double by 2030, and one million people affected in the US.

ALS – also known as Motor Neurone Disease – affects approximately 30,000 people in the US and 5,000 people in the UK; with numbers expected to rise. There are currently no available disease modifying therapies for Parkinson’s or ALS.

Dr Heather Mortiboys from SITraN, who is leading the research, said: “This is a fantastic opportunity to work together with FORMA scientists integrating our complementary expertise to further the development of a treatment for Parkinson’s disease and ALS.

“We are currently recruiting for two post-doctoral researchers for this exciting collaboration. The work stems from the research at SITraN developing novel patient derived models of neurodegenerative diseases and combining these with expert knowledge of the molecular biology underlying Parkinson’s disease and ALS. The team at SITraN includes myself and Dr Laura Ferraiuolo bringing expertise for Parkinson’s disease and ALS respectively.”

Dr Michael Ahlijanian from FORMA added: “We are very excited to collaborate with Dr Mortiboys and the entire team at SITraN, with the intent of bringing novel therapeutics to Parkinson’s disease and ALS patients.

“Integrating the patient-derived cellular systems developed by Dr Mortiboys with the drug discovery expertise at FORMA has the potential to both advance the basic understanding of neurodegenerative disease mechanisms and expedite the development of novel therapeutics.”

FORMA Therapeutics scientists are passionate about discovering and developing medicines that will make a difference in oncology and neurodegenerative disease. The company’s drug discovery engine drives screening and structure-based approaches across broad families of targets involved in tumour metabolism, epigenetics and protein homeostasis.

Leveraging a world-class network of academic investigators, clinical experts and corporate partners, FORMA combines deep biological insight and chemistry expertise to rapidly create high quality, innovative drug candidates.

Ground-breaking work undertaken as part of this collaboration will complement the wider program of research at SITraN and the National Institute for Health Research (NIHR) Sheffield Biomedical Research Centre (BRC).

The NIHR BRC is a research partnership between the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, dedicated to improving the treatment and care of people living with chronic neurological disorders.

Additional Information

For more information about the NIHR Sheffield Biomedical Research Centre please visit: http://sheffieldbrc.nihr.ac.uk/

To find out more about FORMA Therapeutics please visit: http://www.formatherapeutics.com/

The National Institute for Health Research

The National Institute for Health Research (NIHR): improving the health and wealth of the nation through research.

Established by the Department of Health, the NIHR:

  • funds high quality research to improve health
  • trains and supports health researchers
  • provides world-class research facilities
  • works with the life sciences industry and charities to benefit all
  • involves patients and the public at every step

For further information, visit the NIHR website www.nihr.ac.uk

This work uses data provided by patients and collected by the NHS as part of their care and support and would not have been possible without access to this data.

The NIHR recognises and values the role of patient data, securely accessed and stored, both in underpinning and leading to improvements in research and care.

The University of Sheffield

With almost 29,000 of the brightest students from over 140 countries, learning alongside over 1,200 of the best academics from across the globe, the University of Sheffield is one of the world’s leading universities.

A member of the UK’s prestigious Russell Group of leading research-led institutions, Sheffield offers world-class teaching and research excellence across a wide range of disciplines.

Unified by the power of discovery and understanding, staff and students at the university are committed to finding new ways to transform the world we live in.

Sheffield is the only university to feature in The Sunday Times 100 Best Not-For-Profit Organisations to Work For 2018 and for the last eight years has been ranked in the top five UK universities for Student Satisfaction by Times Higher Education.

Sheffield has six Nobel Prize winners among former staff and students and its alumni go on to hold positions of great responsibility and influence all over the world, making significant contributions in their chosen fields.

Global research partners and clients include Boeing, Rolls-Royce, Unilever, AstraZeneca, Glaxo SmithKline, Siemens and Airbus, as well as many UK and overseas government agencies and charitable foundations.

< Back to News